Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Jan-24 4:43 PM View:  | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 04-Nov-23 | Option Exercise | 40,000 | $16.00 | $640,000.00 | 100% 0 to 40.0K | |
| 08-Jan-24 4:43 PM View: | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 04-Nov-23 | Planned Option Sale | 40,000 | $45.29 | $1,811,600.00 | (100%) 40.0K to 0 | |
| 12-Jun-23 4:13 PM View: | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 09-Jun-23 | Planned Option Sale | 20,000 | $45.42 | $908,367.00 | (100%) 20.0K to 0 | |
| 12-Jun-23 4:13 PM View: | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 09-Jun-23 | Option Exercise | 20,000 | $16.00 | $320,000.00 | 100% 0 to 20.0K | |
| 12-Jun-23 4:13 PM View: | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 08-Jun-23 | Option Exercise | 20,000 | $16.00 | $320,000.00 | 100% 0 to 20.0K | |
| 12-Jun-23 4:13 PM View: | Regnante Keith Chief Financial Officer | Keros Therapeutics, Inc. (KROS) | 08-Jun-23 | Planned Option Sale | 20,000 | $47.79 | $955,872.00 | (100%) 20.0K to 0 | |
| 11-Apr-23 4:05 PM View: | Seehra Jasbir Chief Executive Officer Director | Keros Therapeutics, Inc. (KROS) | 08-Apr-23 | Option Exercise | 4,000 | $0.48 | $1,920.00 | 2% 248.86K to 252.86K | |
| 30-Nov-22 4:42 PM View: | Pontifax Management 4 G.P. ... 10% Owner | Keros Therapeutics, Inc. (KROS) | 29-Nov-22 | Exercise (in-the money or at-the-money) Duplicate | 7,176 | $0.00 | $0.72 | (< 1%) 4.64M to 4.63M | |
| 30-Nov-22 4:40 PM View: | Nussbaum Ran Director 10% Owner | Keros Therapeutics, Inc. (KROS) | 29-Nov-22 | Exercise (in-the money or at-the-money) Duplicate | 7,176 | $0.00 | $0.72 | (< 1%) 4.64M to 4.63M | |
| 30-Nov-22 4:38 PM View: | Kariv Tomer Director 10% Owner | Keros Therapeutics, Inc. (KROS) | 29-Nov-22 | Exercise (in-the money or at-the-money) | 7,176 | $0.00 | $0.72 | (< 1%) 4.64M to 4.63M | |
| 19-Jul-22 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 15-Jul-22 | Option Exercise | 46,034 | $0.30 | $13,810.20 | 48% 95.1K to 141.13K | |
| 19-Jul-22 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 15-Jul-22 | Planned Option Sale | 46,034 | $30.00 | $1,381,020.00 | (33%) 141.13K to 95.1K | |
| 15-Jul-22 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 13-Jul-22 | Option Exercise | 1,916 | $0.30 | $574.80 | 2% 95.1K to 97.02K | |
| 15-Jul-22 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 13-Jul-22 | Planned Option Sale | 1,916 | $30.00 | $57,480.00 | (2%) 97.02K to 95.1K | |
| 14-Jun-22 6:57 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 14-Jun-22 | Option Exercise | 9,400 | $0.30 | $2,820.00 | 11% 85.7K to 95.1K | |
| 10-Jun-22 4:12 PM View: | Seehra Jasbir Chief Executive Officer Director | Keros Therapeutics, Inc. (KROS) | 09-Jun-22 | Option Exercise | 5,000 | $0.30 | $1,500.00 | 2% 243.86K to 248.86K | |
| 13-May-22 4:37 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-May-22 | Option Exercise | 5,300 | $0.30 | $1,590.00 | 6% 85.7K to 91.0K | |
| 13-May-22 4:37 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-May-22 | Planned Option Sale | 5,300 | $41.90 | $222,050.00 | (6%) 91.0K to 85.7K | |
| 13-Apr-22 4:36 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Apr-22 | Planned Option Sale | 5,300 | $62.77 | $332,705.00 | (6%) 91.0K to 85.7K | |
| 13-Apr-22 4:36 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Apr-22 | Option Exercise | 5,300 | $0.30 | $1,590.00 | 6% 85.7K to 91.0K | |
| 08-Apr-22 4:21 PM View: | Rovaldi Christopher Chief Operating Officer | Keros Therapeutics, Inc. (KROS) | 06-Apr-22 | Option Exercise | 1,728 | $16.00 | $27,648.00 | 100% 0 to 1.73K | |
| 08-Apr-22 4:21 PM View: | Rovaldi Christopher Chief Operating Officer | Keros Therapeutics, Inc. (KROS) | 06-Apr-22 | Planned Option Sale | 1,728 | $65.00 | $112,320.00 | (100%) 1.73K to 0 | |
| 06-Apr-22 4:49 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 04-Apr-22 | Option Exercise | 7,950 | $0.30 | $2,385.00 | 9% 85.7K to 93.65K | |
| 06-Apr-22 4:49 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 04-Apr-22 | Planned Option Sale | 7,950 | $60.00 | $477,000.00 | (8%) 93.65K to 85.7K | |
| 05-Apr-22 4:31 PM View: | Rovaldi Christopher Chief Operating Officer | Keros Therapeutics, Inc. (KROS) | 01-Apr-22 | Planned Option Sale | 864 | $57.49 | $49,675.10 | (100%) 0.86K to 0 | |
| 05-Apr-22 4:31 PM View: | Rovaldi Christopher Chief Operating Officer | Keros Therapeutics, Inc. (KROS) | 01-Apr-22 | Option Exercise | 864 | $16.00 | $13,824.00 | 100% 0 to 0.86K | |
| 15-Mar-22 4:37 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Mar-22 | Option Exercise | 2,650 | $0.30 | $795.00 | 3% 85.7K to 88.35K | |
| 15-Mar-22 4:37 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Mar-22 | Planned Option Sale | 2,650 | $53.38 | $141,449.00 | (3%) 88.35K to 85.7K | |
| 15-Feb-22 4:26 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Feb-22 | Planned Option Sale | 2,650 | $52.06 | $137,965.00 | (3%) 88.35K to 85.7K | |
| 15-Feb-22 4:26 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Feb-22 | Option Exercise | 2,650 | $0.30 | $795.00 | 3% 85.7K to 88.35K | |
| 13-Jan-22 4:39 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Jan-22 | Option Exercise | 2,650 | $0.30 | $795.00 | 3% 85.7K to 88.35K | |
| 13-Jan-22 4:39 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Jan-22 | Planned Option Sale | 2,650 | $53.75 | $142,447.00 | (3%) 88.35K to 85.7K | |
| 05-Jan-22 7:14 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 05-Jan-22 | Market Sale (Planned) | 4,034 | $58.25 | $234,991.00 | (< 1%) 578.34K to 574.3K | (< 1%) |
| 07-Jan-22 4:35 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 05-Jan-22 | Market Option Sale (Planned) | 2,650 | $60.00 | $159,000.00 | (3%) 88.35K to 85.7K | |
| 07-Jan-22 4:35 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 05-Jan-22 | Option Exercise | 2,650 | $0.30 | $795.00 | 3% 85.7K to 88.35K | |
| 05-Jan-22 7:14 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 04-Jan-22 | Market Sale (Planned) | 20,062 | $57.55 | $1,154,670.00 | (3%) 598.4K to 578.34K | (2%) |
| 05-Jan-22 7:14 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 03-Jan-22 | Market Sale (Planned) | 23,555 | $58.01 | $1,366,460.00 | (4%) 621.95K to 598.4K | (1%) |
| 15-Dec-21 4:48 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 15-Dec-21 | Market Option Sale (Planned) | 735 | $50.00 | $36,750.00 | (< 1%) 86.44K to 85.7K | |
| 15-Dec-21 4:48 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 15-Dec-21 | Option Exercise | 735 | $0.30 | $220.50 | < 1% 85.7K to 86.44K | |
| 15-Dec-21 4:48 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 13-Dec-21 | Option Exercise | 1,915 | $0.30 | $574.50 | 2% 85.7K to 87.61K | |
| 15-Dec-21 4:48 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 13-Dec-21 | Market Option Sale (Planned) | 1,915 | $50.55 | $96,808.30 | (2%) 87.61K to 85.7K | |
| 03-Dec-21 5:05 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 02-Dec-21 | Market Sale (Planned) | 25,338 | $53.57 | $1,357,380.00 | (4%) 647.29K to 621.95K | (1%) |
| 03-Dec-21 5:05 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 01-Dec-21 | Market Sale (Planned) | 22,313 | $54.68 | $1,219,990.00 | (3%) 669.6K to 647.29K | < 1% |
| 12-Nov-21 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Nov-21 | Market Option Sale (Planned) | 5,300 | $59.63 | $316,058.00 | (6%) 91.0K to 85.7K | |
| 12-Nov-21 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 11-Nov-21 | Option Exercise | 5,300 | $0.30 | $1,590.00 | 6% 85.7K to 91.0K | |
| 12-Nov-21 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 10-Nov-21 | Market Option Sale (Planned) | 15,900 | $60.00 | $954,000.00 | (16%) 101.6K to 85.7K | |
| 12-Nov-21 4:40 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 10-Nov-21 | Option Exercise | 15,900 | $0.30 | $4,770.00 | 19% 85.7K to 101.6K | |
| 05-Nov-21 5:06 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 04-Nov-21 | Option Exercise | 10,600 | $0.30 | $3,180.00 | 12% 85.7K to 96.3K | |
| 05-Nov-21 5:06 PM View: | Lachey Jennifer Chief Scientific Officer | Keros Therapeutics, Inc. (KROS) | 04-Nov-21 | Market Option Sale (Planned) | 10,600 | $50.00 | $530,000.00 | (11%) 96.3K to 85.7K | |
| 03-Nov-21 7:04 PM View: | Knowles Julius Director | Keros Therapeutics, Inc. (KROS) | 03-Nov-21 | Market Sale (Planned) | 15,967 | $41.95 | $669,780.00 | (2%) 685.57K to 669.6K | (1%) |
